Condition

Esophageal Squamous Cell Carcinoma (ESCC) clinical trials and research

• 23Clinical trials
• 1New in 30 days
• 5Countries

Newest Esophageal Squamous Cell Carcinoma (ESCC) clinical trials

All recruiting trials (23)

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• Neoadjuvant CTLA-4 and PD-1 blockade with chemoradiotherapy for locally advanced ESCC

  This trial tests whether giving two immune checkpoint inhibitors before surgery, together with chemoradiotherapy, helps patients with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07751055

• PD-1 inhibitors with local therapy at different timings in oligometastatic ESCC

  This study tests whether giving local radiotherapy at different times around PD-1 inhibitor therapy helps people with oligometastatic esophageal squamous cell carcinoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07697859

• Adebrelimab plus chemotherapy before surgery for borderline-resectable esophageal squamous cell carcinoma

  This trial tests whether adding adebrelimab to chemotherapy given before surgery can shrink borderline-resectable ESCC enough to allow curative tumor removal.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07638436

• Adebrelimab with neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

  This study tests whether giving adebrelimab with paclitaxel, carboplatin, and short-course radiotherapy before surgery helps ESCC patients.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07595770

• Starting chemo plus PD-1 immunotherapy before radiation versus giving chemo during radiation for unresectable locally advanced esophageal squamous cell carcinoma

  This trial sees if giving three cycles of chemotherapy with a PD-1 immunotherapy before radiation, followed by maintenance immunotherapy, works better than giving chemotherapy at the same time as radiation followed by the same maintenance for people with unresectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Second Affiliated Hospital of Zunyi Medical University · Zunyi, Guizhou · NCT07559045

• KC1036 plus a PD-1 antibody and platinum chemotherapy for first-line advanced esophageal cancer

  This trial will test whether adding the oral drug KC1036 to a PD-1 antibody (toripalimab) with paclitaxel and cisplatin helps people with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma as first-line treatment.

  Recruiting Phase 2 Beijing Konruns Pharmaceutical Co., Ltd. · Beijing · NCT07481058

• Comparing QLC5508 with chemotherapy for previously treated advanced or metastatic esophageal squamous cell carcinoma

  This trial tests whether QLC5508 works better than standard chemotherapy for adults with advanced or metastatic esophageal squamous cell carcinoma whose cancer progressed after platinum chemotherapy and an immune checkpoint inhibitor.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07463573

• MR-guided radiotherapy dose escalation for esophageal squamous cell carcinoma

  This trial will try higher, MRI-guided radiation doses together with standard chemotherapy for adults with resectable, locally advanced esophageal squamous cell carcinoma to see if it improves tumor control before surgery.

  Recruiting Phase 1 UMC Utrecht · Utrecht, Utrecht · NCT07359417

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Neoadjuvant chemoimmunotherapy followed by endoscopic removal for esophageal squamous cell carcinoma

  This trial tests whether giving chemotherapy plus the PD‑1 drug tislelizumab before surgery can shrink esophageal squamous cell cancers enough to allow removal with an organ‑preserving endoscopic procedure in adults with potentially resectable tumors.

  Recruiting Phase 1 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07317609

• First-line treatment with iparomlimab and tuvonralimab plus chemotherapy for esophageal squamous cell carcinoma

  This will test whether adding two immunotherapy drugs, iparomlimab and tuvonralimab, to chemotherapy helps people with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma as a first-line treatment.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07290010

• StratifiedToripalimab Consolidation After Chemoimmunotherapy and CCRT in Unresectable ESCC

  This trial tests whether giving toripalimab after chemoimmunotherapy and chemoradiation helps people with unresectable locally advanced esophageal squamous cell carcinoma to see if they benefit more than observation.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07246330

• Noninvasive blood miRNA test to screen for multiple gastrointestinal cancers.

  This project will test whether a blood-based microRNA panel can detect several types of gastrointestinal cancer in adults using stored blood samples.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07224750

• Tislelizumab for people 70+ with advanced esophageal squamous-cell cancer who are unfit for chemotherapy

  This trial will try the anti–PD-1 drug tislelizumab, given by IV every 3 weeks, as first-line treatment for people aged 70 and older with advanced esophageal squamous-cell carcinoma who cannot receive platinum chemotherapy to see how many are alive at 6 months.

  Recruiting at 16 sites Phase 2 University Hospital, Clermont-Ferrand · Annecy, Epagny Metz-Tessy and 29 other locations · NCT07205731

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

• ALX2004 for advanced or metastatic EGFR-expressing solid tumors

  This trial will test ALX2004, an antibody-drug conjugate that targets EGFR, in people with advanced or metastatic non-small cell lung, head and neck, esophageal, or colorectal cancer to see if it is safe and shows tumor activity.

  Recruiting at 11 sites Phase 1 ALX Oncology Inc. · La Jolla, California and 11 other locations · NCT07085091

• Immunotherapy plus chemoradiotherapy for older adults with esophageal squamous cell carcinoma

  This project will test if adding immunotherapy to chemoradiotherapy helps people aged 70 and older with esophageal squamous cell carcinoma.

  Recruiting Three Gorges Hospital of Chongqing University · Chongqing, Chongqing Municipality · NCT07080437

• Tislelizumab plus chemoradiation with possible surgery for unresectable esophageal squamous cell carcinoma

  This trial will try combining Tislelizumab with chemoradiotherapy and, if the tumor becomes operable, surgery for people with locally advanced, unresectable esophageal squamous cell carcinoma to see if it improves 2-year survival.

  Recruiting Phase 2 China Medical University Hospital · Kaohsiung City and 7 other locations · NCT07039162

• Comparing two types of chemoradiotherapy for advanced esophageal cancer

  This study is testing whether a new way of giving chemotherapy and radiation can help people with advanced esophageal cancer feel better and stay safe compared to the standard method.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06912074

• Combining sintilimab with chemotherapy and radiotherapy for advanced esophageal cancer

  This study is testing if combining an immunotherapy drug called sintilimab with chemotherapy and radiation can help people with advanced esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06709417

• Neoantigen vaccines for treating esophageal cancer

  This study is testing a new vaccine for people with advanced esophageal cancer to see if it can help them live longer and feel better after their treatment.

  Recruiting Phase 2 Sichuan University · Chengdu, Please Select · NCT06675201

• Investigating AP203 for advanced solid tumors

  This study is testing a new treatment called AP203 to see if it can help adults with advanced solid tumors, like lung cancer and head and neck cancer, feel better and fight their disease.

  Recruiting Phase 1/2 AP Biosciences Inc. · Taipei · NCT05473156

Related topics

Quick answers

How many Esophageal Squamous Cell Carcinoma (ESCC) clinical trials are recruiting right now?

23, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (15 trials), United States (4 trials), Taiwan (2 trials), Netherlands (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1/2: 3, Phase 1: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →